Novel antiviral therapies for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80 percent, according to a new analysis. The finding raises the possibility of greatly reducing, and even eliminating, hepatitis C in the United States if enhanced screening and treatment efforts target high-risk populations.